ArticleAnnals of hematology2025

Targeting relapsed/refractory and MRD + Ph + ALL: olverembatinib-venetoclax bridging enhances allo-HSCT outcome​.

Xiaoyu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.